BioAge Labs (NASDAQ:BIOA) Shares Gap Up – Should You Buy?

BioAge Labs, Inc. (NASDAQ:BIOA) shares gapped up prior to trading on Wednesday . The stock had previously closed at $15.41, but opened at $16.14. BioAge Labs shares last traded at $15.9220, with a volume of 409,767 shares trading hands.

Analysts Set New Price Targets

A number of brokerages have recently commented on BIOA. Weiss Ratings reissued a “sell (d-)” rating on shares of BioAge Labs in a report on Thursday, October 30th. Citigroup upped their target price on shares of BioAge Labs from $10.00 to $15.00 and gave the stock a “buy” rating in a research report on Wednesday, October 29th. Finally, Wall Street Zen upgraded BioAge Labs from a “sell” rating to a “hold” rating in a research report on Saturday, December 6th. One research analyst has rated the stock with a Buy rating and one has issued a Sell rating to the stock. Based on data from MarketBeat, the company presently has a consensus rating of “Hold” and a consensus target price of $15.00.

BioAge Labs Stock Down 6.6%

The stock has a 50-day moving average of $10.77. The company has a market cap of $499.03 million, a price-to-earnings ratio of -9.16 and a beta of 1.38.

BioAge Labs (NASDAQ:BIOA) last released its quarterly earnings data on Thursday, November 6th. The company reported ($0.56) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.67) by $0.11. The company had revenue of $2.05 million for the quarter.

Insider Transactions at BioAge Labs

In other BioAge Labs news, insider Paul D. Rubin sold 18,000 shares of the business’s stock in a transaction dated Tuesday, December 9th. The shares were sold at an average price of $12.00, for a total value of $216,000.00. The transaction was disclosed in a legal filing with the SEC, which is available at this hyperlink. 20.82% of the stock is currently owned by company insiders.

Institutional Trading of BioAge Labs

Large investors have recently modified their holdings of the business. JPMorgan Chase & Co. raised its position in BioAge Labs by 228.7% during the 3rd quarter. JPMorgan Chase & Co. now owns 36,848 shares of the company’s stock valued at $217,000 after purchasing an additional 25,638 shares during the last quarter. Millennium Management LLC increased its stake in shares of BioAge Labs by 749.8% during the third quarter. Millennium Management LLC now owns 306,552 shares of the company’s stock valued at $1,803,000 after buying an additional 270,479 shares during the period. Bank of America Corp DE raised its holdings in shares of BioAge Labs by 46.3% during the third quarter. Bank of America Corp DE now owns 11,119 shares of the company’s stock valued at $65,000 after acquiring an additional 3,517 shares in the last quarter. Occudo Quantitative Strategies LP purchased a new stake in BioAge Labs in the third quarter worth $113,000. Finally, Two Sigma Investments LP boosted its holdings in BioAge Labs by 54.3% in the third quarter. Two Sigma Investments LP now owns 99,669 shares of the company’s stock valued at $586,000 after acquiring an additional 35,068 shares in the last quarter.

About BioAge Labs

BioAge Labs (NASDAQ: BIOA) is a clinical-stage biotechnology company focused on discovering and developing therapies that address age-associated diseases. The company leverages its proprietary analytics platform to mine large-scale human biological data for insights into the molecular mechanisms of aging. By targeting fundamental aging pathways, BioAge aims to create interventions that extend healthspan and treat conditions that disproportionately affect older populations.

At the core of BioAge’s operations is its integrated drug discovery platform, which combines human omics datasets, machine learning algorithms and experimental validation to identify novel drug targets.